SUDEEP PHARMA’S INDIAN SITE RECEIVES EXCiPACT GMP CERTIFICATION AS PHARMACEUTICAL EXCIPIENT SUPPLIERS

Brussels, 21 March 2017 - News Release EXCiPACT

 

EXCiPACT asbl is delighted to announce that the Sudeep Pharma Private Ltd’s Vadodara site in India has recently been awarded an EXCiPACT GMP Certificate from SGS, one of EXCIPACT’s internationally-recognised Certification Bodies.

 

The Certificate demonstrates that the Sudeep Pharma Pvt. Ltd. site in Vadodara, Gujarat, India, manufactures pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. Its scope covers manufacture of different grades of Di basic calcium phosphate, Tri basic calcium phosphate and calcium carbonate for use as pharmaceutical excipients. For full details of all sites that have been EXCiPACT certified to date in 14 Countries (Canada, China, Belgium, France, Germany, The Netherlands, India, Israel, Saudi Arabia, Singapore, Spain, Switzerland, UK and USA), see http://www.excipact.org/certification/certificates/

 

Both SGS and their auditors had to undergo a rigorous assessment process in order to be EXCiPACT Registered. This required the successful completion of the EXCiPACT Training Programme and post-course examination followed by an independently witnessed audit to verify that their competency was to the required standard. SGS also had to have their auditor’s report verified by an independent certification board prior to issuing the certificate.

EU and U.S. pharmaceutical regulations require drug manufacturers to conduct either their own or commission 3rd party physical audits of all their starting material suppliers to demonstrate GMP and/or GDP compliance thus increasing the audit burden. Using GMP and GDP standards designed for excipients, the independent, high quality 3rd Party EXCiPACT Certification Scheme is already helping excipient users and suppliers to reduce their audit burden, save costs and assure quality.

Write a comment

Comments: 0